Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of CH-4051 versus methotrexate in active rheumatoid arthritis with inadequate response to methotrexate monotherapy
2010-019134-27Phase 2Completed
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CH-4051 in rheumatoid arthritis (RA) (5 arms), sponsored by Chelsea Therapeutics International, Ltd. Primary endpoints: Hybrid ACR score at Week 12 and Proportion of patients achieving ACR20. Started Jun 2010; status: completed.
02
Drugs
CH-4051
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-019134-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019134-27.